Benchmark Maintains Buy on Insulet, Lowers Price Target to $185

Benzinga Newsdesk www.benzinga.com Negative 75.9%

Neg 75.9% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $185.